Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer

Recruiting

• Conditions: Squamous Cell Carcinoma of the Head and Neck

• Registration Number: NCT02572778
• Lead Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Brief Summary

The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to:

generate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer

* perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors

* evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options

* evaluate biomarkers of drug sensitivity

* study primary and secondary (acquired) resistance in these models

Detailed Description

Not available

Study Timeline

• Study Start: 2015-09
• Study First Submitted: 2015-09-22
• Study First Submitted QC: 2015-10-08
• Study First Posted: 2015-10-09
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-02
• Last Update Posted: 2024-12-03
• Primary Completion: 2025-12
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• In the first phase, all patients with primary or recurrent/ metastatic disease of head and neck cancer can be included pre-operatively or before a tumor biopsy after obtaining informed consent
• Data on stage, grade, histology, adjuvant treatment, responses, relapse should be available
• Follow-up data should be available
• Patients with recurrent disease are allowed
• Written informed consent

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Identification of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with immunohistochemistry (KI67) on FFPE (fixation followed by paraffin embedding) slides	10 years	Identification of the biomarkers of new cancer therapies for head and neck

Secondary Outcome Measures

Name	Time	Method
Characterization of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with genetic techniques	10 years	Characterization of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with genetic techniques

Trial Locations

Locations (1)

Cliniques universitaires Saint-Luc; 🇧🇪 Brussels, Belgium